Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Journal of Immunology Research, enter your email address in the box below.

Clinical and Developmental Immunology
Volume 2011, Article ID 947858, 10 pages
http://dx.doi.org/10.1155/2011/947858
Review Article

PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors

Francesco Dituri, Antonio Mazzocca, Gianluigi Giannelli, and Salvatore Antonaci

Department of Emergency and Organ Transplantation, Section of Internal Medicine, Allergology and Clinical Immunology, University of Bari Medical School, 70124 Bari, Italy

Received 31 May 2011; Revised 18 August 2011; Accepted 21 August 2011

Academic Editor: Bernhard Fleischer

Copyright © 2011 Francesco Dituri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. C. Cantley, “The phosphoinositide 3-kinase pathway,” Science, vol. 296, no. 5573, pp. 1655–1657, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. J. Guillermet-Guibert, K. Bjorklof, A. Salpekar et al., “The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 24, pp. 8292–8297, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. Saudemont, F. Garçon, H. Yadi et al., “p110γ and p110δ isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 14, pp. 5795–5800, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. Klippel, W. M. Kavanaugh, D. Pot, and L. T. Williams, “A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain,” Molecular and Cellular Biology, vol. 17, no. 1, pp. 338–344, 1997. View at Google Scholar · View at Scopus
  5. R. A. Currie, K. S. Walker, A. Gray et al., “Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1,” Biochemical Journal, vol. 337, no. 2-3, pp. 575–583, 1999. View at Google Scholar · View at Scopus
  6. K. Saito, A. M. Scharenberg, and J. P. Kinet, “Interaction between the Btk PH Domain and Phosphatidylinositol-3,4,5-trisphosphate Directly Regulates Btk,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16201–16206, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. S. Chang, H. Seok, T. K. Kwon et al., “Interaction of elongation factor-1α and pleckstrin homology domain of phospholipase C-γ1 with activating its activity,” Journal of Biological Chemistry, vol. 277, no. 22, pp. 19697–19702, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. C. C. Milburn, M. Deak, S. M. Kelly, N. C. Price, D. R. Alessi, and D. M. F. Van Aalten, “Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change,” Biochemical Journal, vol. 375, no. 3, pp. 531–538, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. I. Sansal and W. R. Sellers, “The biology and clinical relevance of the PTEN tumor suppressor pathway,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2954–2963, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. Kang, A. Denley, B. Vanhaesebroeck, and P. K. Vogt, “Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1289–1294, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. H. A. Dbouk, H. Pang, A. Fiser, and J. M. Backer, “A biochemical mechanism for the oncogenic potential of the p110β catalytic subunit of phosphoinositide 3-kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 46, pp. 19897–19902, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. M. Sun, P. Hillmann, B. T. Hofmann, J. R. Hart, and P. K. Vogt, “Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 35, pp. 15547–15552, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. L. Shayesteh, Y. Lu, W. L. Kuo et al., “PlK3CA is implicated as an oncogene in ovarian cancer,” Nature Genetics, vol. 21, no. 1, pp. 99–102, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. Y. Samuels, Z. Wang, A. Bardelli et al., “High Frequency of Mutations of the PIK3CA Gene in Human Cancers,” Science, vol. 304, no. 5670, p. 554, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. Y. Samuels and T. Waldman, “Oncogenic mutations of PIK3CA in human cancers,” Current Topics in Microbiology and Immunology, vol. 347, pp. 21–41, 2010. View at Google Scholar
  16. S. Jia, Z. Liu, S. Zhang et al., “Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis,” Nature, vol. 454, no. 7205, pp. 776–779, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. H. Lee, G. Poulogiannis, S. Pyne et al., “A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 24, pp. 11002–11007, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. F. Dituri, A. Mazzocca, L. Lupo et al., “PI3K class 1B controls the cell cycle checkpoint promoting cell proliferation in hepato-cellular carcinoma,” International Journal of Cancer. In press. View at Publisher · View at Google Scholar · View at PubMed
  19. C. E. Edling, F. Selvaggi, R. Buus et al., “Key role of phosphoinositide 3-kinase class IB in pancreatic cancer,” Clinical Cancer Research, vol. 16, no. 20, pp. 4928–4937, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. S. Guerreiro, S. Fattet, D. W. Kulesza et al., “A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance,” Molecular Cancer Research, vol. 9, no. 7, pp. 925–935, 2011. View at Publisher · View at Google Scholar · View at PubMed
  21. D. Boller, A. Schramm, K. T. Doepfner et al., “Targeting the phosphoinositide 3-kinase isoform p110δ impairs growth and survival in neuroblastoma cells,” Clinical Cancer Research, vol. 14, no. 4, pp. 1172–1181, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. B. J. Lannutti, S. A. Meadows, S. E. M. Herman et al., “CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability,” Blood, vol. 117, no. 2, pp. 591–594, 2011. View at Publisher · View at Google Scholar · View at PubMed
  23. P. Sujobert, V. Bardet, P. Cornillet-Lefebvre et al., “Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia,” Blood, vol. 106, no. 3, pp. 1063–1066, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. S. Cuní, P. Pérez-Aciego, G. Pérez-Chacón et al., “A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells,” Leukemia, vol. 18, no. 8, pp. 1391–1400, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. B. Seliger, U. Ritz, and S. Ferrone, “Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation,” International Journal of Cancer, vol. 118, no. 1, pp. 129–138, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. V. Groh, R. Rhinehart, H. Secrist, S. Bauer, K. H. Grabstein, and T. Spies, “Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 12, pp. 6879–6884, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. O. J. Finn, “Molecular origins of cancer: cancer immunology,” New England Journal of Medicine, vol. 358, no. 25, pp. 2704–2715, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. C. Borg, A. Jalil, D. Laderach et al., “NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs,” Blood, vol. 104, no. 10, pp. 3267–3275, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. G. Trinchieri, “Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity,” Annual Review of Immunology, vol. 13, pp. 251–276, 1995. View at Google Scholar · View at Scopus
  30. H. Ikeda, L. J. Old, and R. D. Schreiber, “The roles of IFNγ in protection against tumor development and cancer immunoediting,” Cytokine and Growth Factor Reviews, vol. 13, no. 2, pp. 95–109, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. S. H. Apte, P. Groves, S. Olver et al., “IFN-γ inhibits IL-4-induced type 2 cytokine expression by CD8 T cells in vivo and modulates the anti-tumor response,” Journal of Immunology, vol. 185, no. 2, pp. 998–1004, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. M. Wendel, I. E. Galani, E. Suri-Payer, and A. Cerwenka, “Natural killer cell accumulation in tumors is dependent on IFN-γ and CXCR3 ligands,” Cancer Research, vol. 68, no. 20, pp. 8437–8445, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. T. Sasaki, J. Irie-Sasaki, R. G. Jones et al., “Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration,” Science, vol. 287, no. 5455, pp. 1040–4046, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. A. L. Martin, M. D. Schwartz, S. C. Jameson, and Y. Shimizu, “Selective regulation of CD8 effector T cell migration by the p110γ isoform of phosphatidylinositol 3-kinase,” Journal of Immunology, vol. 180, no. 4, pp. 2081–2088, 2008. View at Google Scholar · View at Scopus
  35. B. Q. Ye, Z. H. Geng, L. Ma, and J. G. Geng, “Slit2 regulates attractive eosinophil and repulsive neutrophil chemotaxis through differential srGAP1 expression during lung inflammation,” Journal of Immunology, vol. 185, no. 10, pp. 6294–6305, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. C. F. Fortin, A. Cloutier, T. Ear et al., “A class IA PI3K controls inflammatory cytokine production in human neutrophils,” European Journal of Immunology, vol. 41, no. 6, pp. 1709–1719, 2011. View at Publisher · View at Google Scholar · View at PubMed
  37. M. Haidinger, M. Poglitsch, R. Geyeregger et al., “A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation,” Journal of Immunology, vol. 185, no. 7, pp. 3919–3931, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. L. M. C. Webb, E. Vigorito, M. P. Wymann, E. Hirsch, and M. Turner, “Cutting edge: T cell development requires the combined activities of the p110γ and p110δ catalytic isoforms of phosphatidylinositol 3-kinase,” Journal of Immunology, vol. 175, no. 5, pp. 2783–2787, 2005. View at Google Scholar
  39. W. G. Kerr and F. Colucci, “Inositol phospholipid signaling and the biology of Natural killer cells,” Journal of Innate Immunity, vol. 3, no. 3, pp. 249–257, 2011. View at Publisher · View at Google Scholar · View at PubMed
  40. A. Awasthi, A. Samarakoon, X. Dai, R. Wen, D. Wang, and S. Malarkannan, “Deletion of PI3K-p85α gene impairs lineage commitment, terminal maturation, cytokine generation and cytotoxicity of NK cells,” Genes and Immunity, vol. 9, no. 6, pp. 522–535, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. H. Guo, A. Samarakoon, B. Vanhaesebroeck, and S. Malarkannan, “The p110δ of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation,” Journal of Experimental Medicine, vol. 205, no. 10, pp. 2419–2435, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. J. Wu, Y. Song, A. B. H. Bakker et al., “An activating immunoreceptor complex formed by NKG2D and DAP10,” Science, vol. 285, no. 5428, pp. 730–732, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. J. L. Upshaw and P. J. Leibson, “NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes,” Seminars in Immunology, vol. 18, no. 3, pp. 167–175, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. L. L. Lanier, “Up on the tightrope: Natural killer cell activation and inhibition,” Nature Immunology, vol. 9, no. 5, pp. 495–502, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. C. M. Segovis, R. A. Schoon, C. J. Dick, L. P. Nacusi, P. J. Leibson, and D. D. Billadeau, “PI3K links NKG2D signaling to a CrkL pathway involved in natural killer cell adhesion, polarity, and granule secretion,” Journal of Immunology, vol. 182, no. 11, pp. 6933–6942, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. K. Jiang, B. Zhong, D. L. Gilvary et al., “Syk regulation of phosphoinositide 3-kinase-dependent NK cell function,” Journal of Immunology, vol. 168, no. 7, pp. 3155–3164, 2002. View at Google Scholar · View at Scopus
  47. M. V. Girart, M. B. Fuertes, C. I. Domaica, L. E. Rossi, and N. W. Zwirner, “Engagement of TLR3, TLR7, and NKG2D regulate IFN-γ secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12,” Journal of Immunology, vol. 179, no. 6, pp. 3472–3479, 2007. View at Google Scholar · View at Scopus
  48. M. Ohtani, S. Nagai, S. Kondo et al., “Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells,” Blood, vol. 112, no. 3, pp. 635–643, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. M. Utsugi, K. Dobashi, A. Ono et al., “PI3K p110β positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role,” Journal of Immunology, vol. 182, no. 9, pp. 5225–5231, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. K. Okkenhaug, L. Wu, K. M. Garza et al., “A point mutation in CD28 distinguishes proliferative signals from survival signals,” Nature Immunology, vol. 2, no. 4, pp. 325–332, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. V. Groh, J. Wu, C. Yee, and T. Spies, “Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation,” Nature, vol. 419, no. 6908, pp. 734–738, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. N. Boissel, D. Rea, V. Tieng et al., “BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia,” Journal of Immunology, vol. 176, no. 8, pp. 5108–5116, 2006. View at Google Scholar · View at Scopus
  53. P. Hemon, F. Jean-Louis, K. Ramgolam et al., “MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis,” Journal of Immunology, vol. 186, no. 9, pp. 5173–5183, 2011. View at Publisher · View at Google Scholar · View at PubMed
  54. K. H. Noh, T. H. Kang, J. H. Kim et al., “Activation of Akt as a mechanism for tumor immune evasion,” Molecular Therapy, vol. 17, no. 3, pp. 439–447, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. A. C. Benitez, Z. Dai, H. H. Mann et al., “Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 10, pp. 4081–4086, 2011. View at Publisher · View at Google Scholar · View at PubMed
  56. A. Nicolini and A. Carpi, “Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology,” Medicinal Research Reviews, vol. 29, no. 3, pp. 436–471, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. T. L. Whiteside, “Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention,” Seminars in Cancer Biology, vol. 16, no. 1, pp. 3–15, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. N. Díaz-Valdés, M. Basagoiti, J. Dotor et al., “Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFβ1 in melanoma enhances tumor infiltration and immunosuppression,” Cancer Research, vol. 71, no. 3, pp. 812–821, 2011. View at Publisher · View at Google Scholar · View at PubMed
  59. A. E. Serrano, E. Menares-Castillo, M. Garrido-Tapia et al., “Interleukin 10 decreases MICA expression on melanoma cell surface,” Immunology and Cell Biology, vol. 89, no. 3, pp. 447–457, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. M. Szajnik, M. Czystowska, M. J. Szczepanski, M. Mandapathil, and T. L. Whiteside, “Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg),” PLoS One, vol. 5, no. 7, Article ID e11469, 2010. View at Publisher · View at Google Scholar · View at PubMed
  61. O. V. Efimova and T. W. Kelley, “Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway,” BMC Immunology, vol. 10, article no. 59, 2009. View at Publisher · View at Google Scholar · View at PubMed
  62. D. T. Patton, O. A. Garden, W. P. Pearce et al., “Cutting edge: the phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25+Foxp3+ regulatory T cells,” Journal of Immunology, vol. 177, no. 10, pp. 6598–6602, 2006. View at Google Scholar · View at Scopus
  63. A. Saudemont and F. Colucci, “PI3K signaling in lymphocyte migration,” Cell Cycle, vol. 8, no. 20, pp. 3307–3310, 2009. View at Google Scholar · View at Scopus
  64. M. S. Thomas, J. S. Mitchell, C. C. Denucci, A. L. Martin, and Y. Shimizu, “The p110γ isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites,” Journal of Leukocyte Biology, vol. 84, no. 3, pp. 814–823, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. C.-H. Tang, A. Yamamoto, Y.-T. Lin, Y.-C. Fong, and T.-W. Tan, “Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis,” Biochemical Pharmacology, vol. 79, no. 2, pp. 209–217, 2010. View at Publisher · View at Google Scholar · View at PubMed
  66. M. Krusch, J. Salih, M. Schlicke et al., “The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro,” Journal of Immunology, vol. 183, no. 12, pp. 8286–8294, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. K. Kohga, T. Takehara, T. Tatsumi et al., “Sorafenib inhibits the shedding of major histocompatibility complex class i-related chain a on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9,” Hepatology, vol. 51, no. 4, pp. 1264–1273, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. H. Ghebeh, C. Lehe, E. Barhoush et al., “Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule,” Breast Cancer Research, vol. 12, no. 4, article no. R48, 2010. View at Publisher · View at Google Scholar · View at PubMed
  69. J. Salih, J. Hilpert, T. Placke et al., “The BCR/ABL-inhibitors Imatinib, nilotinib and dasatinib differentially affect NK cell reactivity,” International Journal of Cancer, vol. 127, no. 9, pp. 2119–2128, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. E. Zebedin, O. Simma, C. Schuster et al., “Leukemic challenge unmasks a requirement for PI3K{delta} in NK cell-mediated tumor surveillance,” Blood, vol. 112, no. 12, pp. 4655–4664, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. S. Cuní, P. Pérez-Aciego, G. Pérez-Chacón et al., “A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells,” Leukemia, vol. 18, no. 8, pp. 1391–1400, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. S. E. M. Herman, A. L. Gordon, A. J. Wagner et al., “Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals,” Blood, vol. 116, no. 12, pp. 2078–2088, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. A. González-García, J. Sánchez-Ruiz, J. M. Flores, and A. C. Carrera, “Phosphatidylinositol 3-kinase γ inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer,” Gastroenterology, vol. 138, no. 4, pp. 1374–1383, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. C. Crane, A. Panner, R. O. Pieper, J. Arbiser, and A. T. Parsa, “Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function,” Journal of Immunotherapy, vol. 32, no. 6, pp. 585–592, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. M. Czystowska, J. Han, M. J. Szczepanski et al., “IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death,” Cell Death and Differentiation, vol. 16, no. 5, pp. 708–718, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. D. Nagorsen and P. A. Baeuerle, “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Experimental Cell Research, vol. 317, no. 9, pp. 1255–1260, 2011. View at Publisher · View at Google Scholar · View at PubMed
  77. A. Corti, M. Giovannini, C. Belli, and E. Villa, “Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: focus on TLR9 agonists, IMiDs and NGR-TNF,” Journal of Oncology, vol. 2010, Article ID 732680, 8 pages, 2010. View at Publisher · View at Google Scholar · View at PubMed
  78. S. E. M. Herman, R. Lapalombella, A. L. Gordon et al., “The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia,” Blood, vol. 117, no. 16, pp. 4323–4327, 2011. View at Publisher · View at Google Scholar · View at PubMed
  79. N. M. Dagia, G. Agarwal, D. V. Kamath et al., “A preferential p110α/γ PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-κB-dependent manner,” American Journal of Physiology, vol. 298, no. 4, pp. C929–C941, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. A. Fougerat, S. Gayral, P. Gourdy et al., “Genetic and pharmacological targeting of phosphoinositide 3-kinase-γ reduces atherosclerosis and favors plaque stability by modulating inflammatory processes,” Circulation, vol. 117, no. 10, pp. 1310–1317, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. D. H. Rodrigues, M. D. C. Vilela, L. D. S. Barcelos, V. Pinho, M. M. Teixeira, and A. L. Teixeira, “Absence of PI3Kγ leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 222, no. 1-2, pp. 90–94, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. C. Ferrandi, V. Ardissone, P. Ferro et al., “Phosphoinositide 3-kinase γ inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment,” Journal of Pharmacology and Experimental Therapeutics, vol. 322, no. 3, pp. 923–930, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. K. S. Lee, S. J. Park, S. R. Kim et al., “Phosphoinositide 3-kinase-δ inhibitor reduces vascular permeability in a murine model of asthma,” Journal of Allergy and Clinical Immunology, vol. 118, no. 2, pp. 403–409, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. A. Basu, A. Hoerning, D. Datta et al., “Cutting edge: vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-γ production,” Journal of Immunology, vol. 184, no. 2, pp. 545–549, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. H. Ogino, M. Hanibuchi, S. Kakiuchi et al., “E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor,” Molecular Cancer Therapeutics, vol. 10, no. 7, pp. 1218–1228, 2011. View at Publisher · View at Google Scholar · View at PubMed
  86. M. Yamamoto, H. Kikuchi, M. Ohta et al., “TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche,” Cancer Research, vol. 68, no. 23, pp. 9754–9762, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. R. K. Sharma, A. K. Srivastava, E. S. Yolcu et al., “SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model,” Vaccine, vol. 28, no. 36, pp. 5794–5802, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. P. Rizza, F. Moretti, and F. Belardelli, “Recent advances on the immunomodulatory effects of IFN-α: implications for cancer immunotherapy and autoimmunity,” Autoimmunity, vol. 43, no. 3, pp. 204–209, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. L. Fong and E. J. Small, “Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5275–5283, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. H. Wang, E. R. Rayburn, W. Wang, E. R. Kandimalla, S. Agrawal, and R. Zhang, “Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy,” Molecular Cancer Therapeutics, vol. 5, no. 8, pp. 2106–2114, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. H. Wang, E. R. Rayburn, W. Wang, E. R. Kandimalla, S. Agrawal, and R. Zhang, “Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9,” Molecular Cancer Therapeutics, vol. 5, no. 6, pp. 1585–1592, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. E. R. Rayburn, W. Wang, Z. Zhang, M. Li, R. Zhang, and H. Wang, “Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy,” Prostate, vol. 66, no. 15, pp. 1653–1663, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. C. Galustian, M. C. Labarthe, J. B. Bartlett, and A. G. Dalgleish, “Thalidomide-derived immunomodulatory drugs as therapeutic agents,” Expert Opinion on Biological Therapy, vol. 4, no. 12, pp. 1963–1970, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. M. Reck and U. Gatzemeier, “Targeted therapies: thalidomide in lung cancer therapywhat have we learned?” Nature Reviews Clinical Oncology, vol. 7, no. 3, pp. 134–135, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. C. M. Koebel, W. Vermi, J. B. Swann et al., “Adaptive immunity maintains occult cancer in an equilibrium state,” Nature, vol. 450, no. 7171, pp. 903–907, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus